Trends in the Mortality of Hepatocellular Carcinoma in the United States
Primary liver cancer mortality rates have been increasing in the US, but reported decreases among 35–49 year olds may foreshadow future declines. We sought to use age-period-cohort (APC) modeling to evaluate the contribution of cohort effects to hepatocellular carcinoma (HCC) mortality trends in the US.
Data on HCC mortality were obtained from the Centers for Disease Control and Prevention National Center for Health Statistics WONDER Online Multiple Cause of Death database, 1999–2015. Crude mortality rates were plotted by gender and age at death. Gender-specific restricted cubic spline APC models were fit to determine influence of birth cohort on incidence of HCC mortality, in reference to the 1940 birth cohort.
Highest mortality rates were found among men ages 70+, with steepest increase in mortality observed among men 55–69 years old. Similar trends were found among females. Accounting for the cohort effect in the APC model markedly improved model fit (likelihood ratio test p < 0.001). Relative to the 1940 birth cohort, risk of mortality due to HCC was significantly higher in later as well as earlier cohorts.
HCC-associated mortality continues to increase, secondary to an increase in the risk of HCC-associated mortality in more recent birth cohorts among both men and women.
KeywordsHepatocellular carcinoma Mortality
Alcoholic liver disease
Hepatitis B Virus
Hepatitis C Virus
Model for end stage liver disease
Nonalcoholic fatty liver disease
Compliance with Ethical Standards
All authors report no disclosures.
EWB, DT, AK, DM, XZ, JC, TMP designed the study. EWB and DT performed the data analysis. EWB, DT, AK, DM, XZ, JC, and TMP interpreted the data. EWB and DT prepared the manuscript. EWB, DT, AK, DM, XZ, JC, and TMP provided critical review.
- 2.Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017; 23(6):836–844. doi: 10.1002/lt.24758.
- 3.Murali AR, Patil S, Phillips KT, Voigt M. Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis. Transplantation. 2017; 101(8):e249–e257. doi: 10.1097/TP.0000000000001730.
- 5.Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent MELD scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int. 2017. doi: 10.1111/tri.12967.
- 7.Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017; 15(2):296–304. doi: 10.1007/s11938-017-0133-3.
- 8.OPTN OPaTN. National Data. Organ by Status. Current U.S. Waiting List. For Type = Registrations. Based on OPTN data as of February 7. 2017. 2017. [Available from: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#.
- 9.OPTN OPaTN. National Data, Transplants by Donor Type, U.S. Transplants Performed January 1, 1988 - December 31, 2016, For Organ = Liver. 2017 [Available from: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#.
- 10.OPTN OPaTN. National Data. Removal Reasons by Year. Removed from the waiting list January 1, 1995 - December 31, 2016. For Organ = Liver. Based on OPTN data as of February 7, 2017. 2017. [Available from: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#.
- 15.Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017.Google Scholar
- 16.Statistics. C-NCfDCaPNCfH. Multiple Cause of Death 1999–2015 on CDC WONDER Online Database, Released December 2016.Google Scholar
- 18.Rutherford MJ, Lambert PC, Thompson JR. Age–period–cohort modeling. The Stata Journal. 2010; 10(4):606–27.Google Scholar
- 26.Prevention. CCfDCa. Morbidity and Mortality Weekly Report. State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs — United States, 2015–2016. 2017. [Available from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6618a2.htm.
- 27.Prevention. CCfDCa. Surveillance for Viral Hepatitis - United States, 2015. 2017. [Available from: https://www.cdc.gov/hepatitis/statistics/2015surveillance/commentary.htm.